816 results on '"Verhey, Frans R. J."'
Search Results
102. Development and feasibility of Inlife: A pilot study of an online social support intervention for informal caregivers of people with dementia
- Author
-
Dam, Alieske E. H., primary, van Boxtel, Martin P. J., additional, Rozendaal, Nico, additional, Verhey, Frans R. J., additional, and de Vugt, Marjolein E., additional
- Published
- 2017
- Full Text
- View/download PDF
103. Coronary heart disease and risk for cognitive impairment or dementia: Systematic review and meta-analysis
- Author
-
Deckers, Kay, primary, Schievink, Syenna H. J., additional, Rodriquez, Maria M. F., additional, van Oostenbrugge, Robert J., additional, van Boxtel, Martin P. J., additional, Verhey, Frans R. J., additional, and Köhler, Sebastian, additional
- Published
- 2017
- Full Text
- View/download PDF
104. ESTIMATED GLOMERULAR FILTRATION RATE, (MICRO) ALBUMINURIA AND COGNITIVE PERFORMANCE: THE MAASTRICHT STUDY
- Author
-
Martens, Remy, Kooman, Jeroen P., Stehouwer, Coen D. A., Dagnelie, Pieter C., van der Kallen, Carla J. H., Koster, Annemarie, Kroon, Abraham A., Leunissen, Karel M. L., Nijpels, Giel, van der Sande, Frank M., Schaper, Nicolaas C., Sep, Simone J. S., Verhey, Frans R. J., van Boxtel, Martin P. J., Schram, Miranda T., Henry, Ronald M. A., RS: NUTRIM - R3 - Chronic inflammatory disease and wasting, Promovendi NTM, MUMC+: MA Nefrologie (9), Interne Geneeskunde, RS: CARIM - R3.01 - Vascular complications of diabetes and the metabolic syndrome, RS: CAPHRI School for Public Health and Primary Care, Epidemiologie, Sociale Geneeskunde, RS: CARIM - R3.02 - Hypertension and target organ damage, Psychiatrie & Neuropsychologie, and RS: FPN NPPP I
- Published
- 2016
105. Prevalence of Vascular Risk Factors in Different Stages of Prodromal Alzheimer’s Disease and Its Influence on Cognitive Decline
- Author
-
Bos, I., Vos, SJB, Kornhuber, Johannes, Wiltfang, J., Maier, W., Peters, O., Rüther, E., Engelborghs, Sebastiaan, Niemantsverdriet, Ellis, De Roeck, E.E., Tsolaki, Magda, Freud-Levi, Y., Johannsen, P., Vandenberghe, R., Lleó, A, Alcolea, D., Frisoni, Giovanni B, Galluzzi, S., Nobili, F., Morbelli, S., Drzezga, A., Didic, M., van Berckel, BNM, Salmon, E., Bastin, C., Dauby, S., Santana, I., Baldeiras, I., Mendoça, A., Silva, D., Wallin, A., Nordlund, A., Foskett, N., Coloma, P., Alexander, M., Wientzek-Fleischmann, A., Nevado-Holgado, Alejo J, Gungabissoon, U., Novak, G.P., Gordon, M.F., Wallin, A.K., Hampel, H., Soininen, H., Scheltens, P., Verhey, Frans R J, Visser, Pieter Jelle, Clinical sciences, and Neurology
- Subjects
Medicine(all) ,vascular risk factor ,cognitive decline ,Alzheimer’s disease ,Prodomal - Published
- 2016
106. Effectiveness of an online social support intervention for caregivers of people with dementia: the study protocol of a randomised controlled trial
- Author
-
Dam, Alieske E. H., primary, de Vugt, Marjolein E., additional, van Boxtel, Martin P. J., additional, and Verhey, Frans R. J., additional
- Published
- 2017
- Full Text
- View/download PDF
107. Cognitive changes in prevalent and incident cardiovascular disease: a 12-year follow-up in the Maastricht Aging Study (MAAS)
- Author
-
Schievink, Syenna H J, primary, van Boxtel, Martin P J, additional, Deckers, Kay, additional, van Oostenbrugge, Robert J, additional, Verhey, Frans R J, additional, and Köhler, Sebastian, additional
- Published
- 2017
- Full Text
- View/download PDF
108. Dealing with daily challenges in dementia (deal-id study): process evaluation of the experience sampling method intervention ‘Partner in Sight’ for spousal caregivers of people with dementia
- Author
-
van Knippenberg, Rosalia J. M., primary, de Vugt, Marjolein E., additional, Smeets, Claudia M. J., additional, Myin-Germeys, Inez, additional, Verhey, Frans R. J., additional, and Ponds, Rudolf W., additional
- Published
- 2017
- Full Text
- View/download PDF
109. Cerebral Pathology and Cognition in Diabetes: The Merits of Multiparametric Neuroimaging
- Author
-
van Bussel, Frank C. G., primary, Backes, Walter H., additional, Hofman, Paul A. M., additional, van Oostenbrugge, Robert J., additional, van Boxtel, Martin P. J., additional, Verhey, Frans R. J., additional, Steinbusch, Harry W. M., additional, Schram, Miranda T., additional, Stehouwer, Coen D. A., additional, Wildberger, Joachim E., additional, and Jansen, Jacobus F. A., additional
- Published
- 2017
- Full Text
- View/download PDF
110. The clinical course and interrelations of dementia related symptoms
- Author
-
Haaksma, Miriam L., primary, Leoutsakos, Jeannie-Marie S., additional, Bremer, Jonne A. E., additional, Aalten, Pauline, additional, Ramakers, Inez H. G. B., additional, Verhey, Frans R. J., additional, Olde Rikkert, Marcel G. M., additional, and Melis, René J. F., additional
- Published
- 2017
- Full Text
- View/download PDF
111. Lifestyle for Brain Health (LIBRA): a new model for dementia prevention
- Author
-
Schiepers, Olga J. G., primary, Köhler, Sebastian, additional, Deckers, Kay, additional, Irving, Kate, additional, O'Donnell, Catherine A., additional, van den Akker, Marjan, additional, Verhey, Frans R. J., additional, Vos, Stephanie J. B., additional, de Vugt, Marjolein E., additional, and van Boxtel, Martin P. J., additional
- Published
- 2017
- Full Text
- View/download PDF
112. Diagnostic impact of [18F]flutemetamol PET in early-onset dementia
- Author
-
Zwan, Marissa D., primary, Bouwman, Femke H., additional, Konijnenberg, Elles, additional, van der Flier, Wiesje M., additional, Lammertsma, Adriaan A., additional, Verhey, Frans R. J., additional, Aalten, Pauline, additional, van Berckel, Bart N. M., additional, and Scheltens, Philip, additional
- Published
- 2017
- Full Text
- View/download PDF
113. A profile of The Clinical Course of Cognition and Comorbidity in Mild Cognitive Impairment and Dementia Study (The 4C study): two complementary longitudinal, clinical cohorts in the Netherlands
- Author
-
Liao, Weiqi, primary, Hamel, Renske E. G., additional, Olde Rikkert, Marcel G. M., additional, Oosterveld, Saskia M., additional, Aalten, Pauline, additional, Verhey, Frans R. J., additional, Scheltens, Philip, additional, Sistermans, Nicole, additional, Pijnenburg, Yolande A. L., additional, van der Flier, Wiesje M., additional, Ramakers, Inez H. G. B., additional, and Melis, René J. F., additional
- Published
- 2016
- Full Text
- View/download PDF
114. Blood-Brain Barrier Leakage in Patients with Early Alzheimer Disease
- Author
-
van de Haar, Harm J., primary, Burgmans, Saartje, additional, Jansen, Jacobus F. A., additional, van Osch, Matthias J. P., additional, van Buchem, Mark A., additional, Muller, Majon, additional, Hofman, Paul A. M., additional, Verhey, Frans R. J., additional, and Backes, Walter H., additional
- Published
- 2016
- Full Text
- View/download PDF
115. Target risk factors for dementia prevention: a systematic review and Delphi consensus study on the evidence from observational studies
- Author
-
Deckers, Kay, van Boxtel, Martin P. J., Schiepers, Olga J. G., de Vugt, Marjolein, Munoz Sanchez, Juan Luis, Anstey, Kaarin J., Brayne, Carol, Dartigues, Jean-Francois, Engedal, Knut, Kivipelto, Miia, Ritchie, Karen, Starr, John M., Yaffe, Kristine, Irving, Kate, Verhey, Frans R. J., Kohler, Sebastian, Promovendi MHN, RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, Section Neuropsychology, RS: FPN NPPP I, and Psychiatrie & Neuropsychologie
- Subjects
prevention ,public health ,risk factors ,epidemiology ,dementia - Abstract
ObjectiveDementia has a multifactorial etiology, but the importance of individual health and lifestyle related risk factors is often uncertain or based on few studies. The goal of this paper is to identify the major modifiable risk factors for dementia as a first step in developing an effective preventive strategy and promoting healthy late life cognitive functioning. MethodsA mixed-method approach combined findings from a systematic literature review and a Delphi consensus study. The literature search was conducted in PubMed and updated an earlier review by the United States National Institutes of Health from 2010. We reviewed the available evidence from observational epidemiological studies. The online Delphi study asked eight international experts to rank and weigh each risk factor for its importance for dementia prevention. ResultsOut of 3127 abstracts, 291 were included in the review. There was good agreement between modifiable risk factors identified in the literature review and risk factors named spontaneously by experts. After triangulation of both methods and re-weighting by experts, strongest support was found for depression, (midlife) hypertension, physical inactivity, diabetes, (midlife) obesity, hyperlipidemia, and smoking, while more research is needed for coronary heart disease, renal dysfunction, diet, and cognitive activity. ConclusionsFindings provide good support for several somatic and lifestyle factors and will be used to inform the design of a new multicenter trial into dementia prevention.
- Published
- 2015
116. Prevalence of cerebral amyloid pathology in persons without dementia
- Author
-
Jansen, Willemijn J., Ossenkoppele, Rik, Knol, Dirk L., Tijms, Betty M., Scheltens, Philip, Verhey, Frans R. J., Visser, Pieter Jelle, Aalten, Pauline, Aarsland, Dag, Alcolea, Daniel, Alexander, Myriam, Roe, Catherine M., Rot, Uros, Rowe, Christopher C., Rüther, Eckart, Sabri, Osama, Sanchez-Juan, Páscual, Santana, Isabel, Sarazin, Marie, Schröder, Johannes, Schütte, Christin, Almdahl, Ina S., Seo, Sang W., Soetewey, Femke, Soininen, Hilkka, Spiru, Luiza, Struyfs, Hanne, Teunissen, Charlotte E., Tsolaki, Magda, Vandenberghe, Rik, Verbeek, Marcel M., Villemagne, Victor L., Arnold, Steven E., Vos, Stephanie J. B., van Waalwijk van Doorn, Linda J. C., Waldemar, Gunhild, Wallin, Anders, Wallin, Åsa K., Wiltfang, Jens, Wolk, David A., Zboch, Marzena, Zetterberg, Henrik, Baldeiras, Inês, Barthel, Henryk, van Berckel, Bart N. M., Bibeau, Kristen, Blennow, Kaj, Brooks, David J., van Buchem, Mark A., Camus, Vincent, Cavedo, Enrica, Chen, Kewei, Chetelat, Gael, Cohen, Ann D., Drzezga, Alexander, Engelborghs, Sebastiaan, Fagan, Anne M., Fladby, Tormod, Fleisher, Adam S., van der Flier, Wiesje M., Ford, Lisa, Förster, Stefan, Fortea, Juan, Foskett, Nadia, Frederiksen, Kristian S., Freund-Levi, Yvonne, Frisoni, Giovanni B., Froelich, Lutz, Gabryelewicz, Tomasz, Gill, Kiran Dip, Gkatzima, Olymbia, Gómez-Tortosa, Estrella, Gordon, Mark Forrest, Grimmer, Timo, Hampel, Harald, Hausner, Lucrezia, Hellwig, Sabine, Herukka, Sanna-Kaisa, Hildebrandt, Helmut, Ishihara, Lianna, Ivanoiu, Adrian, Jagust, William J., Johannsen, Peter, Kandimalla, Ramesh, Kapaki, Elisabeth, Klimkowicz-Mrowiec, Aleksandra, Klunk, William E., Köhler, Sebastian, Koglin, Norman, Kornhuber, Johannes, Kramberger, Milica G., Van Laere, Koen, Landau, Susan M., Lee, Dong Young, de Leon, Mony, Lisetti, Viviana, Lleó, Alberto, Madsen, Karine, Maier, Wolfgang, Marcusson, Jan, Mattsson, Niklas, De Mendonça, Alexandre, Meulenbroek, Olga, Meyer, Philipp T., Mintun, Mark A., Mok, Vincent, Molinuevo, José Luis, Møllergård, Hanne M., Morris, John C., Mroczko, Barbara, Van der Mussele, Stefan, Na, Duk L., Newberg, Andrew, Nordberg, Agneta, Nordlund, Arto, Novak, Gerald P., Paraskevas, George P., Parnetti, Lucilla, Perera, Gayan, Peters, Oliver, Popp, Julius, Prabhakar, Sudesh, Rabinovici, Gil D., Ramakers, Inez H. G. B., Rami, Lorena, Resende de Oliveira, Catarina, Rinne, Juha O., Rodrigue, Karen M., Rodríguez-Rodríguez, Eloy, and Repositório da Universidade de Lisboa
- Abstract
Copyright © 2015 American Medical Association. All rights reserved., Importance: Cerebral amyloid-β aggregation is an early pathological event in Alzheimer disease (AD), starting decades before dementia onset. Estimates of the prevalence of amyloid pathology in persons without dementia are needed to understand the development of AD and to design prevention studies. Objective: To use individual participant data meta-analysis to estimate the prevalence of amyloid pathology as measured with biomarkers in participants with normal cognition, subjective cognitive impairment (SCI), or mild cognitive impairment (MCI). Data sources: Relevant biomarker studies identified by searching studies published before April 2015 using the MEDLINE and Web of Science databases and through personal communication with investigators. Study selection: Studies were included if they provided individual participant data for participants without dementia and used an a priori defined cutoff for amyloid positivity. Data extraction and synthesis: Individual records were provided for 2914 participants with normal cognition, 697 with SCI, and 3972 with MCI aged 18 to 100 years from 55 studies. Main outcomes and measures: Prevalence of amyloid pathology on positron emission tomography or in cerebrospinal fluid according to AD risk factors (age, apolipoprotein E [APOE] genotype, sex, and education) estimated by generalized estimating equations. Results: The prevalence of amyloid pathology increased from age 50 to 90 years from 10% (95% CI, 8%-13%) to 44% (95% CI, 37%-51%) among participants with normal cognition; from 12% (95% CI, 8%-18%) to 43% (95% CI, 32%-55%) among patients with SCI; and from 27% (95% CI, 23%-32%) to 71% (95% CI, 66%-76%) among patients with MCI. APOE-ε4 carriers had 2 to 3 times higher prevalence estimates than noncarriers. The age at which 15% of the participants with normal cognition were amyloid positive was approximately 40 years for APOE ε4ε4 carriers, 50 years for ε2ε4 carriers, 55 years for ε3ε4 carriers, 65 years for ε3ε3 carriers, and 95 years for ε2ε3 carriers. Amyloid positivity was more common in highly educated participants but not associated with sex or biomarker modality. Conclusions and relevance: Among persons without dementia, the prevalence of cerebral amyloid pathology as determined by positron emission tomography or cerebrospinal fluid findings was associated with age, APOE genotype, and presence of cognitive impairment. These findings suggest a 20- to 30-year interval between first development of amyloid positivity and onset of dementia., The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under EMIF grant agreement No. 115372, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in-kind contribution. BIOMARKAPD is an EU Joint Programme–Neurodegenerative Disease Research (JPND) project. The project is supported through national funding organizations under the aegis of JPND (http://www.jpnd.eu). In the Netherlands, this is ZonMw. The DESCRIPA study was funded by the European Commission within the 5th framework program (QLRT-2001-2455). The EDAR study was funded by the European Commission as part of the 6th framework programme (contract No. 37670). This research was performed within the framework of the Center for Translational Molecular Medicine (CTTM) (http://www.ctmm.nl), project LeARN (grant 02N-101). The AIBL study was funded in part by the study partners (Australian Commonwealth Scientific Industrial and Research Organization [CSIRO], Edith Cowan University [ECU], Mental Health Research Institute [MHRI], Alzheimer’s Australia [AA], National Ageing Research Institute [NARI], Austin Health, CogState, Hollywood Private Hospital, Sir Charles Gardner Hospital). The study also received support from the National Health and Medical Research Council (NHMRC) and the Dementia Collaborative Research Centres program (DCRC2), as well as ongoing funding from the Science and Industry Endowment Fund (SIEF). Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health grant U01 AG024904) and the US Department of Defense ADNI (W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging and the National Institute of Biomedical Imaging and Bioengineering and through generous contributions from the following: Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; BioClinica; Biogen Idec; Bristol-Myers Squibb Company; Eisai; Elan Pharmaceuticals; Eli Lilly; F. Hoffmann-La Roche and its affiliated company Genentech; GE Healthcare; Innogenetics; IXICO; Janssen Alzheimer Immunotherapy Research & Development; Johnson & Johnson Pharmaceutical Research & Development; Medpace; Merck; Meso Scale Diagnostics; NeuroRx Research; Novartis Pharmaceuticals; Pfizer; Piramal Imaging; Servier; Synarc; and Takeda Pharmaceutical. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (http://www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. The Dementia Competence Network (DCN) has been supported by a grant from the German Federal Ministry of Education and Research (BMBF): Kompetenznetz Demenzen (01GI0420). Additional funding related to the randomized clinical trials came from Janssen-Cilag and Merz Pharmaceuticals. The latter funds were exclusively used for personnel, pharmaceuticals, blistering and shipment of medication, and monitoring and as capitation fees for recruiting centers. Funding source for the Chandigarh study is the Indian Council of Medical Research (ICMR), India. Funding for the St Louis contribution was provided by the National Institute on Aging (P50 AG005681, P01 AG003991, and P01 AG026276); Fred Simmons and Olga Mohan, and the Charles and Joanne Knight Alzheimer’s Research Initiative of the Washington University Knight Alzheimer’s Disease Research Center. The Tours study received financial support of the French Ministry of Health grant PHRC-N 2008 1004 and the EC-FP6-project DiMI, LSHB-CT-2005-512146. The Caen study was funded by Agence Nationale de la Recherche, Programme Hospitalier de Recherche Clinique, Région Basse Normandie, and Institut National de la Santé et de la Recherche Médicale (Inserm). The research leading to the Munich contribution to the Mattsson multicenter study has received funding from the program “Investissements d’avenir” (ANR-10-IAIHU-06). The study from Pittsburgh was supported by National Institutes of Health grants (P50 AG005133, R37 AG025516, P01 AG025204). The New York contributions to the Mattsson multicenter study were in part supported by P30 AG008051, R01 AG13616, R01 AG022374, and R01 AG12101. Data from Brescia in this article were collected by Translational Outpatient Memory Clinic (TOMC) working group at IRCCS Fatebenefratelli in Brescia, Italy. Contributors to the TOMC are G. Amicucci, S. Archetti, L. Benussi, G. Binetti, L. Bocchio-Chiavetto, C. Bonvicini, E. Canu, F. Caobelli, E. Cavedo, E. Chittò, M. Cotelli, M. Gennarelli, S. Galluzzi, C. Geroldi, R. Ghidoni, R. Giubbini, U. P. Guerra, G. Kuffenschin, G. Lussignoli, D. Moretti, B. Paghera, M. Parapini, C. Porteri, M. Romano, S. Rosini, I. Villa, R. Zanardini, and O. Zanetti. The JPND Project is supported in Italy by the Italian Ministry of Health. The assembling of the TU Munich data set was supported in part by the German research foundation (Deutsche Forschungsgemeinschaft) (HE 4560/1-2, DR 445/3-1 and DR 445/4-1 to A.D.), and by a KKF grant for clinical research of the Technische Universität München (to A.D. and T.G.). The Florbetaben phase 2 study from which data were derived for this multicenter evaluation was sponsored by Bayer Healthcare/Piramal Imaging (Berlin, Germany). This work was supported by the University of Antwerp Research Fund; the Alzheimer Research Foundation (SAO-FRA); the Research Foundation Flanders (FWO); the Agency for Innovation by Science and Technology (IWT); the Belgian Science Policy Office Interuniversity Attraction Poles (IAP) program; and the Flemish Government–initiated Methusalem excellence grant.
- Published
- 2015
117. Differences in neuropsychiatric symptoms between nursing home residents with young-onset dementia and late-onset dementia.
- Author
-
Appelhof, Britt, Van Duinen-van Den IJssel, Jeannette C. L., Bakker, Christian, Koopmans, Raymond T. C. M., Zwijsen, Sandra A., Smalbrugge, Martin, Verhey, Frans R. J., de Vugt, Marjolein E., and Zuidema, Sytse U.
- Subjects
DIAGNOSIS of dementia ,AGE factors in disease ,APATHY ,COMPARATIVE studies ,DEMENTIA ,MATHEMATICAL models ,NURSING home patients ,NURSING care facilities ,HEALTH outcome assessment ,PSYCHIATRIC drugs ,DISEASE management ,THEORY ,SEVERITY of illness index ,STATISTICAL models ,DELAYED onset of disease ,EVALUATION ,SYMPTOMS - Abstract
Objective: The aims of the current study are (1) to explore the differences in neuropsychiatric symptoms (NPS) between young-onset dementia (YOD) and late-onset dementia (LOD), and (2) to investigate whether the possible differences can be attributed to differences in dementia subtype, gender, psychotropic drug use (PDU), or dementia severity. Method: Three hundred and eighty-six nursing home (NH) residents with YOD and 350 with LOD were included. Multilevel modeling was used to compare NPS between the groups. Furthermore, dementia subtype, gender, PDU, and dementia severity were added to the crude multilevel models to investigate whether the possible differences in NPS could be attributed to these characteristics. Results: Higher levels of apathy were found in NH residents with YOD. After the characteristics were added to the models, also lower levels of verbally agitated behaviors were found in YOD. Conclusion: We recommend that special attention be paid to interventions targeting apathy in YOD. Although no differences in other NPS were found, the PDU rates were higher in YOD, suggesting that the threshold for the use of PDU in the management of NPS is lower. This underscores the need for appropriate attention to non-pharmacological interventions for the management of NPS in YOD. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
118. Dealing with daily challenges in dementia (deal-id study): process evaluation of the experience sampling method intervention ‘Partner in Sight’ for spousal caregivers of people with dementia.
- Author
-
van Knippenberg, Rosalia J. M., de Vugt, Marjolein E., Smeets, Claudia M. J., Myin-Germeys, Inez, Verhey, Frans R. J., and Ponds, Rudolf W.
- Subjects
TREATMENT of dementia ,CONTENT analysis ,EMOTIONS ,EXPERIENCE ,MEDICAL protocols ,RESEARCH evaluation ,PSYCHOLOGY of Spouses ,QUALITATIVE research ,ACTIVITIES of daily living ,QUANTITATIVE research ,RANDOMIZED controlled trials ,CAREGIVER attitudes ,DESCRIPTIVE statistics - Abstract
Objectives: This study describes the process evaluation of the experience sampling method (ESM) intervention ‘Partner in Sight’ for spousal caregivers of people with dementia. The aim was to determine internal and external validity of the intervention and provide information for future implementation in clinical practice. Method: Qualitative and quantitative data on sampling quality (recruitment and randomization, reach) and intervention quality (relevance and feasibility, adherence to protocol) were evaluated using descriptive statistics and conventional content analysis. Results: The participation rate included 31.4%. Due to recruitment difficulties and time constraints the original goal to include 90 caregivers was not met. The intervention was largely performed according to protocol and well received by the participants. Overall, the ESM-derived feedback was considered supportive and increased participants’ awareness of their feelings and behavior. A large variance was found in the extent to which caregivers applied the feedback into their daily lives. The importance of the personal coach to provide face-to-face feedback and stimulate caregivers to implement new insights into their daily lives was emphasized. Suggestions for improvement were to reduce the time intensity of the program, to better tailor the program content to one's personal situation, and to improve the ESM device. Conclusion: Although recruitment barriers were encountered, results indicate that future implementation of the ESM intervention ‘Partner in Sight’ is likely to be feasible in regular health care. If the intervention turns out to be (cost-) effective, a fine-tuned version of the program could be a valuable addition to the current health care system. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
119. Characteristics of double care demanding patients in a mental health care setting and a nursing home setting: results from the SpeCIMeN study
- Author
-
Collet, Janine, primary, de Vugt, Marjolein E., additional, Verhey, Frans R. J., additional, Engelen, Noud J. J. A., additional, and Schols, Jos M. G. A., additional
- Published
- 2016
- Full Text
- View/download PDF
120. Advanced Glycation End Product (AGE) Accumulation in the Skin is Associated with Depression: The Maastricht Study
- Author
-
van Dooren, Fleur E. P., primary, Pouwer, Frans, additional, Schalkwijk, Casper G., additional, Sep, Simone J. S., additional, Stehouwer, Coen D. A., additional, Henry, Ronald M. A., additional, Dagnelie, Pieter C., additional, Schaper, Nicolaas C., additional, van der Kallen, Carla J. H., additional, Koster, Annemarie, additional, Denollet, Johan, additional, Verhey, Frans R. J., additional, and Schram, Miranda T., additional
- Published
- 2016
- Full Text
- View/download PDF
121. The Cognition and Affect after Stroke - a Prospective Evaluation of Risks (CASPER) study: rationale and design
- Author
-
Douven, Elles, primary, Schievink, Syenna H. J., additional, Verhey, Frans R. J., additional, van Oostenbrugge, Robert J., additional, Aalten, Pauline, additional, Staals, Julie, additional, and Köhler, Sebastian, additional
- Published
- 2016
- Full Text
- View/download PDF
122. Dealing with daily challenges in dementia (deal-id study): effectiveness of the experience sampling method intervention ’Partner in Sight’ for spousal caregivers of people with dementia: design of a randomized controlled trial
- Author
-
van Knippenberg, Rosalia J. M., primary, de Vugt, Marjolein E., additional, Ponds, Rudolf W., additional, Myin-Germeys, Inez, additional, and Verhey, Frans R. J., additional
- Published
- 2016
- Full Text
- View/download PDF
123. Effectiveness of the blended care self-management program “Partner in Balance” for early-stage dementia caregivers: study protocol for a randomized controlled trial
- Author
-
Boots, Lizzy M. M., primary, de Vugt, Marjolein E., additional, Kempen, Gertrudis I. J. M., additional, and Verhey, Frans R. J., additional
- Published
- 2016
- Full Text
- View/download PDF
124. Psychological and personality factors in type 2 diabetes mellitus, presenting the rationale and exploratory results from The Maastricht Study, a population-based cohort study
- Author
-
van Dooren, Fleur E. P., primary, Denollet, Johan, additional, Verhey, Frans R. J., additional, Stehouwer, Coen D. A., additional, Sep, Simone J. S., additional, Henry, Ronald M. A., additional, Kremers, Stef P. J., additional, Dagnelie, Pieter C., additional, Schaper, Nicolaas C., additional, van der Kallen, Carla J. H., additional, Koster, Annemarie, additional, Pouwer, Frans, additional, and Schram, Miranda T., additional
- Published
- 2016
- Full Text
- View/download PDF
125. The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases
- Author
-
Reijs, Babette L. R., primary, Teunissen, Charlotte E., additional, Goncharenko, Nikolai, additional, Betsou, Fay, additional, Blennow, Kaj, additional, Baldeiras, Inês, additional, Brosseron, Frederic, additional, Cavedo, Enrica, additional, Fladby, Tormod, additional, Froelich, Lutz, additional, Gabryelewicz, Tomasz, additional, Gurvit, Hakan, additional, Kapaki, Elisabeth, additional, Koson, Peter, additional, Kulic, Luka, additional, Lehmann, Sylvain, additional, Lewczuk, Piotr, additional, Lleó, Alberto, additional, Maetzler, Walter, additional, de Mendonça, Alexandre, additional, Miller, Anne-Marie, additional, Molinuevo, José L., additional, Mollenhauer, Brit, additional, Parnetti, Lucilla, additional, Rot, Uros, additional, Schneider, Anja, additional, Simonsen, Anja Hviid, additional, Tagliavini, Fabrizio, additional, Tsolaki, Magda, additional, Verbeek, Marcel M., additional, Verhey, Frans R. J., additional, Zboch, Marzena, additional, Winblad, Bengt, additional, Scheltens, Philip, additional, Zetterberg, Henrik, additional, and Visser, Pieter Jelle, additional
- Published
- 2015
- Full Text
- View/download PDF
126. Effectiveness of a Blended Care Self-Management Program for Caregivers of People With Early-Stage Dementia (Partner in Balance): Randomized Controlled Trial.
- Author
-
Boots, Lizzy M. M., de Vugt, Marjolein E., Kempen, Gertrudis I. J. M., Verhey, Frans R. J., Boots, Lizzy Mm, Kempen, Gertrudis Ijm, and Verhey, Frans Rj
- Subjects
DEMENTIA ,CAREGIVERS ,PSYCHOLOGICAL stress ,TECHNOLOGY ,THERAPEUTICS ,MENTAL health ,QUALITY of life ,TREATMENT of dementia ,RESEARCH ,RESEARCH methodology ,EVALUATION research ,MEDICAL cooperation ,COMPARATIVE studies ,PSYCHOLOGICAL tests ,RANDOMIZED controlled trials ,PSYCHOLOGY of caregivers ,QUESTIONNAIRES - Abstract
Background: The benefits of electronic health support for dementia caregivers are increasingly recognized. Reaching caregivers of people with early-stage dementia could prevent high levels of burden and psychological problems in the later stages.Objective: The current study evaluates the effectiveness of the blended care self-management program, Partner in Balance, compared to a control group.Methods: A single-blind randomized controlled trial with 81 family caregivers of community-dwelling people with mild dementia was conducted. Participants were randomly assigned to either the 8-week, blended care self-management Partner in Balance program (N=41) or a waiting-list control group (N=40) receiving usual care (low-frequent counseling). The program combines face-to-face coaching with tailored Web-based modules. Data were collected at baseline and after 8 weeks in writing by an independent research assistant who was blinded to the treatment. The primary proximal outcome was self-efficacy (Caregiver Self-Efficacy Scale) and the primary distal outcome was symptoms of depression (Center for Epidemiological Studies Depression Scale). Secondary outcomes included mastery (Pearlin Mastery Scale), quality of life (Investigation Choice Experiments for the Preferences of Older People), and psychological complaints (Hospital Anxiety and Depression Scale-Anxiety and Perceived Stress Scale).Results: A significant increase in favor of the intervention group was demonstrated for self-efficacy (care management, P=.002; service use P=.001), mastery (P=.001), and quality of life (P=.032). Effect sizes were medium for quality of life (d=0.58) and high for self-efficacy care management and service use (d=0.85 and d=0.93, respectively) and mastery (d=0.94). No significant differences between the groups were found on depressive symptoms, anxiety, and perceived stress.Conclusions: This study evaluated the first blended-care intervention for caregivers of people with early-stage dementia and demonstrated a significant improvement in self-efficacy, mastery, and quality of life after receiving the Partner in Balance intervention, compared to a waiting-list control group receiving care as usual. Contrary to our expectations, the intervention did not decrease symptoms of depression, anxiety, or perceived stress. However, the levels of psychological complaints were relatively low in the study sample. Future studies including long-term follow up could clarify if an increase in self-efficacy results in a decrease or prevention of increased stress and depression. To conclude, the program can provide accessible preventative care to future generations of caregivers of people with early-stage dementia.Trial Registration: Netherlands Trial Register NTR4748; http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=4748 (Archived by WebCite at http://www.webcitation.org/6vSb2t9Mg). [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
127. Characteristics of double care demanding patients in a mental health care setting and a nursing home setting: results from the SpeCIMeN study.
- Author
-
Collet, Janine, de Vugt, Marjolein E., Verhey, Frans R. J., Engelen, Noud J. J. A., and Schols, Jos M. G. A.
- Subjects
COGNITION disorders ,MENTAL illness ,NEEDS assessment ,NURSING home patients ,NURSING care facilities ,SCIENTIFIC observation ,PSYCHIATRIC hospitals ,PSYCHOTHERAPY patients ,QUALITY of life ,COMORBIDITY ,SAMPLE size (Statistics) ,STATISTICAL significance ,CROSS-sectional method ,PSYCHOLOGY - Abstract
Background: Older patients suffering from a combination of psychiatric disorders and physical illnesses and/or dementia are called Double Care Demanding patients (DCDs). Special wards for DCDs within Dutch nursing homes (NHs) and mental health care institutions (MHCIs) offer a unique opportunity to obtain insight into the characteristics and needs of this challenging population. Methods: This observational cross-sectional study collected data from 163 DCDs admitted to either a NH or a MHCI providing specialized care for DCDs. Similarities and differences between both DCD groups are described. Results: Neuropsychiatric symptoms were highly prevalent in all DCDs but significantly more in MHCI-DCDs. Cognitive disorders were far more present in NH-DCDs, while MHCI-DCDs often suffered from multiple psychiatric disorders. The severity of comorbidities and care dependency were equally high among all DCDs. NH-DCDs expressed more satisfaction in overall quality of life. Conclusions: The institutionalized elderly DCD population is very heterogeneous. Specific care arrangements are necessary because the severity of a patient's physical illness and the level of functional impairment seem to be equally important as the patient's behavioural, psychiatric and social problems. Further research should assess the adequacy of the setting assignment and the professional skills needed to provide adequate care for elderly DCDs. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
128. Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer's Disease.
- Author
-
Geijselaers, Stefan L. C., Aalten, Pauline, Ramakers, Inez H. G. B., De Deyn, Peter Paul, Heijboer, Annemieke C., Koek, Huiberdina L., OldeRikkert, Marcel G. M., Papma, Janne M., Reesink, Fransje E., Smits, Lieke L., Stehouwer, Coen D. A., Teunissen, Charlotte E., Verhey, Frans R. J., van der Flier, Wiesje M., Biessels, Geert Jan, and Parelsnoer Institute Neurodegenerative Diseases study group
- Subjects
CEREBROSPINAL fluid ,ALZHEIMER'S disease ,MAGNETIC resonance imaging ,MILD cognitive impairment ,DEMENTIA ,COGNITION disorders diagnosis ,BRAIN metabolism ,APOLIPOPROTEINS ,BRAIN ,CELLULAR signal transduction ,COGNITION disorders ,INSULIN ,NEUROPSYCHOLOGICAL tests ,NERVE tissue proteins ,PEPTIDES ,PSYCHOLOGICAL tests ,DISEASE complications - Abstract
Background: Abnormal insulin signaling in the brain has been linked to Alzheimer's disease (AD).Objective: To evaluate whether cerebrospinal fluid (CSF) insulin levels are associated with cognitive performance and CSF amyloid-β and Tau. Additionally, we explore whether any such association differs by sex or APOE ɛ4 genotype.Methods: From 258 individuals participating in the Parelsnoer Institute Neurodegenerative Diseases, a nationwide multicenter memory clinic population, we selected 138 individuals (mean age 66±9 years, 65.2% male) diagnosed with subjective cognitive impairment (n = 45), amnestic mild cognitive impairment (n = 44), or AD (n = 49), who completed a neuropsychological assessment, including tests of global cognition and memory performance, and who underwent lumbar puncture. We measured CSF levels of insulin, amyloid-β1-42, total (t-)Tau, and phosphorylated (p-)Tau.Results: CSF insulin levels did not differ between the diagnostic groups (p = 0.136). Across the whole study population, CSF insulin was unrelated to cognitive performance and CSF biomarkers of AD, after adjustment for age, sex, body mass index, diabetes status, and clinic site (all p≥0.131). Importantly, however, we observed effect modification by sex and APOE ɛ4 genotype. Specifically, among women, higher insulin levels in the CSF were associated with worse global cognition (standardized regression coefficient -0.483; p = 0.008) and higher p-Tau levels (0.353; p = 0.040). Among non-carriers of the APOE ɛ4 allele, higher CSF insulin was associated with higher t-Tau (0.287; p = 0.008) and p-Tau (0.246; p = 0.029).Conclusion: Our findings provide further evidence for a relationship between brain insulin signaling and AD pathology. It also highlights the need to consider sex and APOE ɛ4 genotype when assessing the role of insulin. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
129. The Role of Hyperglycemia, Insulin Resistance, and Blood Pressure in Diabetes-Associated Differences in Cognitive Performance-The Maastricht Study.
- Author
-
Geijselaers, Stefan L. C., Sep, Simone J. S., Claessens, Danny, Schram, Miranda T., van Boxte, Martin P. J., Henry, Ronald M. A., Verhey, Frans R. J., Kroon, Abraham A., Dagnelie, Pieter C., Schalkwijk, Casper G., van der Kallen, Carla J. H., Biessels, Geert Jan, and Stehouwer, Coen D. A.
- Subjects
GLUCOSE metabolism ,HYPERGLYCEMIA ,INSULIN resistance ,BLOOD pressure ,GLYCOSYLATED hemoglobin ,DIABETES prevention - Abstract
Objective: To study to what extent differences in cognitive performance between individuals with different glucose metabolism status are potentially attributable to hyperglycemia, insulin resistance, and blood pressure-related variables.Research Design and Methods: We used cross-sectional data from 2,531 participants from the Maastricht Study (mean age ± SD, 60 ± 8 years; 52% men; n = 666 with type 2 diabetes), all of whom completed a neuropsychological test battery. Hyperglycemia was assessed by a composite index of fasting glucose, postload glucose, glycated hemoglobin (HbA1c), and tissue advanced glycation end products; insulin resistance by the HOMA of insulin resistance index; and blood pressure-related variables included 24-h ambulatory pressures, their weighted SDs, and the use of antihypertensive medication. Linear regression analyses were used to estimate mediating effects.Results: After adjustment for age, sex, and education, individuals with type 2 diabetes, compared with those with normal glucose metabolism, performed worse in all cognitive domains (mean differences in composite z scores for memory -0.087, processing speed -0.196, executive function and attention -0.182; P values <0.032), whereas individuals with prediabetes did not. Diabetes-associated differences in processing speed and executive function and attention were largely explained by hyperglycemia (mediating effect 79.6% [bootstrapped 95% CI 36.6; 123.4] and 50.3% [0.6; 101.2], respectively) and, for processing speed, to a lesser extent by blood pressure-related variables (17.7% [5.6; 30.1]), but not by insulin resistance. None of the factors explained the differences in memory function.Conclusions: Our cross-sectional data suggest that early glycemic and blood pressure control, perhaps even in the prediabetic stage, may be promising therapeutic targets for the prevention of diabetes-associated decrements in cognitive performance. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
130. Cost-Utility of Using Alzheimer's Disease Biomarkers in Cerebrospinal Fluid to Predict Progression from Mild Cognitive Impairment to Dementia.
- Author
-
Handels, Ron L H, Wimo, Anders, Dodel, Richard, Kramberger, Milica G, Visser, Pieter Jelle, Molinuevo, José Luis, Verhey, Frans R J, and Winblad, Bengt
- Abstract
Background: Diagnostic research criteria for Alzheimer's disease support the use of biomarkers in the cerebrospinal fluid (CSF) to improve the accuracy of the prognosis regarding progression to dementia for people with mild cognitive impairment (MCI).Objective: The aim of this study was to estimate the potential incremental cost-effectiveness ratio of adding CSF biomarker testing to the standard diagnostic workup to determine the prognosis for patients with MCI.Methods: In an early technology assessment, a mathematical simulation model was built, using available evidence on added prognostic value as well as expert opinion to estimate the incremental costs and quality-adjusted life years (QALYs) of 20,000 virtual MCI patients with (intervention strategy) and without (control strategy) relying on CSF, from a health-care sector perspective and with a 5-year time horizon.Results: Adding the CSF test improved the accuracy of prognosis by 11%. This resulted in an average QALY gain of 0.046 and € 432 additional costs per patient, representing an incremental cost-effectiveness ratio of € 9,416.Conclusion: The results show the potential of CSF biomarkers in current practice from a health-economics perspective. This result was, however, marked by a high degree of uncertainty, and empirical research is required into the impact of a prognosis on worrying, false-positive/negative prognosis, and stigmatization. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
131. The benefit of a geriatric nurse practitioner in a multidisciplinary diagnostic service for people with cognitive disorders
- Author
-
Ament, Bart H L, primary, Wolfs, Claire A G, additional, Kempen, Gertrudis I J M, additional, Ambergen, Ton, additional, Verhey, Frans R J, additional, and De Vugt, Marjolein E, additional
- Published
- 2015
- Full Text
- View/download PDF
132. Qualitative study on needs and wishes of early-stage dementia caregivers: the paradox between needing and accepting help
- Author
-
Boots, Lizzy M. M., primary, Wolfs, Claire A. G., additional, Verhey, Frans R. J., additional, Kempen, Gertrudis I. J. M., additional, and de Vugt, Marjolein E., additional
- Published
- 2015
- Full Text
- View/download PDF
133. Target risk factors for dementia prevention: a systematic review and Delphi consensus study on the evidence from observational studies
- Author
-
Deckers, Kay, primary, van Boxtel, Martin P. J., additional, Schiepers, Olga J. G., additional, de Vugt, Marjolein, additional, Muñoz Sánchez, Juan Luis, additional, Anstey, Kaarin J., additional, Brayne, Carol, additional, Dartigues, Jean-Francois, additional, Engedal, Knut, additional, Kivipelto, Miia, additional, Ritchie, Karen, additional, Starr, John M, additional, Yaffe, Kristine, additional, Irving, Kate, additional, Verhey, Frans R. J., additional, and Köhler, Sebastian, additional
- Published
- 2014
- Full Text
- View/download PDF
134. Optimizing the use of expert panel reference diagnoses in diagnostic studies of multidimensional syndromes
- Author
-
Handels, Ron L H, primary, Wolfs, Claire A G, additional, Aalten, Pauline, additional, Bossuyt, Patrick M M, additional, Joore, Manuela A, additional, Leentjens, Albert F G, additional, Severens, Johan L, additional, and Verhey, Frans R J, additional
- Published
- 2014
- Full Text
- View/download PDF
135. Werkzaamheid en bijwerkingen van antipsychotica voor neuropsychiatrische symptomen bij dementie; een systematische review
- Author
-
Zuidema, S U, van Iersel, M B, Verhey, Frans R. J., Koopmans, R. T. C. M., and Olde Rikkert, M G M
- Subjects
Aggression ,Benzodiazepines ,Treatment Outcome ,Psychotic Disorders ,Haloperidol ,Humans ,Dementia ,Risperidone ,Antipsychotic Agents - Abstract
Doel. Beoordelen van werkzaamheid en bijwerkingen van antipsychotica voor neuropsychiatrische symptomen bij dementie. Nagaan van bewijs voor de waarschuwing voor cerebrovasculaire bijwerkingen van atypische antipsychotica. Opzet. Systematische review. Methode. Selectie in Medline, Cinahl, PsycINFO, Embase en het Cochrane central register of controlled trials (1980-2005) van gerandomiseerde dubbelblinde studies met ‘intention-to-treat’-analyse naar werkzaamheid en bijwerkingen van antipsychotica voor neuropsychiatrische symptomen bij dementie. Deze studies werden gestandaardiseerd beoordeeld op kwaliteit. Resultaten. Van de 950 gevonden artikelen werden 14 studies geselecteerd over het effect van haloperidol, risperidon, olanzapine, quetiapine, tiapride, loxapine en perfenazine. Haloperidol, risperidon en olanzapine bleken in 7 van de 10 onderzoeken werkzamer voor de behandeling van agressie en psychose dan placebo. Bij onderlinge vergelijking van klassieke en atypische antipsychotica was er geen statistisch significant verschil. De meest voorkomende bijwerkingen waren extrapiramidale symptomen en sufheid. Risperidon had deze bijwerkingen in lagere doseringen minder dan haloperidol en olanzapine, maar risperidon en olanzapine lieten in twee studies een verhoogde kans op beroerte zien. Conclusie. Klassieke en atypische antipsychotica vertonen een vergelijkbare werkzaamheid en alleen risperidon lijkt vooral in lagere doseringen minder (extrapiramidale) bijwerkingen te geven. Het bijwerkingenprofiel is matig omschreven in het gepubliceerde onderzoek en de waarschuwingen voor een verhoogde sterfte kunnen op basis hiervan niet worden bevestigd.
- Published
- 2006
136. Gait Speed and Grip Strength Reflect Cognitive Impairment and Are Modestly Related to Incident Cognitive Decline in Memory Clinic Patients With Subjective Cognitive Decline and Mild Cognitive Impairment: Findings From the 4C Study.
- Author
-
Hooghiemstra, Astrid M., Ramakers, Inez H. G. B., Sistermans, Nicole, Pijnenburg, Yolande A. L., Aalten, Pauline, Hamel, Renske E. G., Melis, René J. F., Verhey, Frans R. J., Olde Rikkert, Marcel G. M., Scheltens, Philip, van der Flier, Wiesje M., and 4C Study Group
- Subjects
FRAGILITY (Psychology) ,COGNITIVE ability ,PERSEVERATION (Psychology) ,CRYSTALLIZED intelligence ,ALZHEIMER'S disease ,ALZHEIMER'S disease treatment ,DEMENTIA ,PROGNOSIS ,COMPARATIVE studies ,GAIT in humans ,GRIP strength ,LONGITUDINAL method ,NEUROPSYCHOLOGICAL tests ,RESEARCH methodology ,MEDICAL cooperation ,PSYCHOLOGICAL tests ,REGRESSION analysis ,RESEARCH ,EVALUATION research ,DISEASE progression ,EXECUTIVE function - Abstract
Background: Prospective studies in the general population show that slow gait speed is associated with cognitive decline and clinical progression to dementia. However, longitudinal studies in memory clinic populations are mostly lacking. We aimed to study the association between gait speed and grip strength and cognitive functioning at baseline and cognitive decline over time in memory clinic patients with subjective cognitive decline and mild cognitive impairment.Methods: We included 309 patients (age 70 ± 9 years, 108 [35%] women, Mini-Mental State Examination 27 ± 3 points). Baseline gait speed was assessed over 15 feet, grip strength with a hydraulic hand dynamometer. Cognitive functioning was assessed annually with a comprehensive test battery during 3 years.Results: Age- and gender-adjusted linear mixed models showed that slower gait speed was related to worse baseline attention, memory, information processing speed, and verbal fluency. Longitudinally, gait speed was related to decline in information processing speed and executive functioning. Weaker grip strength was related to worse baseline information processing speed and executive functioning but there were no longitudinal associations. Cox proportional hazards models revealed no significant associations with clinical progression.Conclusions: Our findings suggest that markers of physical performance are related to current cognitive status and modestly related to cognitive decline but are seemingly not useful as an early marker of incident clinical progression. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
137. Modifiable Risk Factors for Prevention of Dementia in Midlife, Late Life and the Oldest-Old: Validation of the LIBRA Index.
- Author
-
Vos, Stephanie J. B., Van Boxtel, Martin P. J., Schiepers, Olga J. G., Deckers, Kay, De Vugt, Marjolein, Carriére, Isabelle, Dartigues, Jean-François, Peres, Karine, Artero, Sylvaine, Ritchie, Karen, Galluzzo, Lucia, Scafato, Emanuele, Frisoni, Giovanni B., Huisman, Martijn, Comijs, Hannie C., Sacuiu, Simona F., Skoog, Ingmar, Irving, Kate, O'donnell, Catherine A., and Verhey, Frans R. J.
- Subjects
DEMENTIA prevention ,AGING ,DEMENTIA risk factors ,MIDDLE age ,ALZHEIMER'S disease risk factors ,PHYSICAL activity measurement ,HYPERTENSION epidemiology ,AGE distribution ,COMPARATIVE studies ,DEMENTIA ,MENTAL depression ,DIABETES ,HEALTH planning ,RESEARCH methodology ,MEDICAL cooperation ,QUESTIONNAIRES ,RESEARCH ,SMOKING ,EVALUATION research - Abstract
Background: Recently, the LIfestyle for BRAin health (LIBRA) index was developed to assess an individual's prevention potential for dementia.Objective: We investigated the predictive validity of the LIBRA index for incident dementia in midlife, late life, and the oldest-old.Methods: 9,387 non-demented individuals were recruited from the European population-based DESCRIPA study. An individual's LIBRA index was calculated solely based on modifiable risk factors: depression, diabetes, physical activity, hypertension, obesity, smoking, hypercholesterolemia, coronary heart disease, and mild/moderate alcohol use. Cox regression was used to test the predictive validity of LIBRA for dementia at follow-up (mean 7.2 y, range 1-16).Results: In midlife (55-69 y, n = 3,256) and late life (70-79 y, n = 4,320), the risk for dementia increased with higher LIBRA scores. Individuals in the intermediate- and high-risk groups had a higher risk of dementia than those in the low-risk group. In the oldest-old (80-97 y, n = 1,811), higher LIBRA scores did not increase the risk for dementia.Conclusion: LIBRA might be a useful tool to identify individuals for primary prevention interventions of dementia in midlife, and maybe in late life, but not in the oldest-old. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
138. Diagnostic impact of [18F]flutemetamol PET in early-onset dementia.
- Author
-
Zwan, Marissa D., Bouwman, Femke H., Konijnenberg, Elles, van der Flier, Wiesje M., Lammertsma, Adriaan A., Verhey, Frans R. J., Aalten, Pauline, van Berckel, Bart N. M., and Scheltens, Philip
- Subjects
POSITRON emission tomography ,DIAGNOSIS of dementia ,AMYLOID ,PATIENT management ,ALZHEIMER'S disease ,PATHOLOGY - Abstract
Background: Early-onset dementia patients often present with atypical clinical symptoms, hampering an accurate clinical diagnosis. The purpose of the present study was to assess the diagnostic impact of the amyloid-positron emission tomography (PET) imaging agent [
18 F]flutemetamol in early-onset dementia patients, in terms of change in (confidence in) diagnosis and patient management plan. Methods: This prospective bi-center study included 211 patients suspected of early-onset dementia who visited a tertiary memory clinic. Patients were eligible with Mini Mental State Examination ≥ 18 and age at diagnosis ≤ 70 years and in whom the diagnostic confidence was <90% after routine diagnostic work-up. All patients underwent [18F]flutemetamol PET, which was interpreted as amyloid-negative or amyloid-positive based on visual rating. Before and after disclosing the PET results, we assessed the diagnostic confidence (using a visual analog scale of 0-100%) and clinical diagnosis. The impact of [18 F]flutemetamol PET on the patient management plan was also evaluated. Results: [18 F]flutemetamol PET scans were positive in 133 out of 211 (63%) patients, of whom 110 out of 144 (76%) patients had a pre-PET Alzheimer's disease (AD) diagnosis and 23 out of 67 (34%) patients had a non-AD diagnosis. After disclosure of PET results, 41/211 (19%) diagnoses changed. Overall, diagnostic confidence increased from 69 ± 12% to 88 ± 15% after disclosing PET results (P < 0.001; in 87% of patients). In 79 (37%) patients, PET results led to a change in patient management and predominantly the initiation of AD medication when PET showed evidence for amyloid pathology. Conclusions: [18F]flutemetamol PET changed clinical diagnosis, increased overall diagnostic confidence, and altered the patient management plan. Our results suggest that amyloid PET may have added value over the standardized diagnostic work-up in early-onset dementia patients with uncertain clinical diagnosis. This study provides evidence for the recommendations put forward in the appropriate use criteria for amyloid PET in clinical practice. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
139. Dementia risk in renal dysfunction.
- Author
-
Deckers, Kay, Camerino, Ileana, van Boxtel, Martin P. J., Verhey, Frans R. J., Irving, Kate, Brayne, Carol, Kivipelto, Miia, Starr, John M., Yaffe, Kristine, de Leeuw, Peter W., and Köhler, Sebastian
- Published
- 2017
- Full Text
- View/download PDF
140. Advanced Glycation End Product (AGE) Accumulation in the Skin is Associated with Depression: The Maastricht Study.
- Author
-
Dooren, Fleur E. P., Pouwer, Frans, Schalkwijk, Casper G., Sep, Simone J. S., Stehouwer, Coen D. A., Henry, Ronald M. A., Dagnelie, Pieter C., Schaper, Nicolaas C., der Kallen, Carla J. H., Koster, Annemarie, Denollet, Johan, Verhey, Frans R. J., and Schram, Miranda T.
- Subjects
MENTAL depression ,DISEASE prevalence ,PATHOLOGICAL physiology ,MORTALITY risk factors ,TYPE 2 diabetes risk factors - Abstract
Background: Depression is a highly prevalent disease with a high morbidity and mortality risk. Its pathophysiology is not entirely clear. However, type 2 diabetes is an important risk factor for depression. One mechanism that may explain this association may include the formation of advanced glycation end products (AGEs). We therefore investigated the association of AGEs with depressive symptoms and depressive disorder. In addition, we examined whether the potential association was present for somatic and/or cognitive symptoms of depression.Methods: Cross-sectional data were used from the Maastricht Study (N = 862, mean age 59.8 ± 8.5 years, 55% men). AGE accumulation was measured with skin autofluorescence (SAF) by use of the AGE Reader. Plasma levels of protein-bound pentosidine were measured with high-performance liquid chromatography and fluorescence detection. Nε-(carboxymethyl)lysine (CML) and Nε-(carboxyethyl)lysine (CEL) were measured with ultraperformance liquid chromatography and tandem mass spectrometry. Depressive symptoms and depressive disorder were assessed by the nine-item Patient Health Questionnaire and the Mini-International Neuropsychiatric Interview.Results: Higher SAF was associated with depressive symptoms (β = 0.42, 95% CI 0.12-0.73, P = .007) and depressive disorder (OR = 1.42, 95% CI 1.04-1.95, P = .028) after adjustment for age, sex, type 2 diabetes, smoking, BMI, and kidney function. Plasma pentosidine, CML, and CEL were not independently associated with depressive symptoms and depressive disorder.Conclusions: This study shows that AGE accumulation in the skin is independently associated with higher levels of depressive symptoms and depressive disorder. This association is present for both somatic and cognitive symptoms of depression. This might suggest that AGEs are involved in the development of depression. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
141. A profile of The Clinical Course of Cognition and Comorbidity in Mild Cognitive Impairment and Dementia Study (The 4C study): two complementary longitudinal, clinical cohorts in the Netherlands.
- Author
-
Weiqi Liao, Hamel, Renske E. G., Olde Rikkert, Marcel G. M., Oosterveld, Saskia M., Aalten, Pauline, Verhey, Frans R. J., Scheltens, Philip, Sistermans, Nicole, Pijnenburg, Yolande A. L., van der Flier, Wiesje M., Ramakers, Inez H. G. B., and Melis, René J. F.
- Subjects
MILD cognitive impairment ,DIAGNOSIS of dementia ,COGNITION ,COMORBIDITY ,QUALITY of life ,DIAGNOSIS - Abstract
Background: Heterogeneous disease trajectories of mild cognitive impairment (MCI) and dementia are frequently encountered in clinical practice, but there is still insufficient knowledge to understand the reasons and mechanisms causing this heterogeneity. In addition to correlates of the disorder, patient characteristics such as their health status, social environment, comorbidities and frailty may contribute to variability in trajectories over time. The current paper outlines the study design and the study population of and provides an overview of the data collected in the Clinical Course of Cognition and Comorbidity in Mild Cognitive Impairment (4C-MCI cohort, n = 315) and Dementia (4C-Dementia cohort, n = 331) Study. Methods: The two complementary longitudinal cohorts part of the 4C study began enrolment in March 2010. Participants were prospectively recruited from three collaborating Dutch Alzheimer Centers, with three annual follow-up assessments after baseline. Extensive neuropsychological assessments, and detailed profiling of comorbidities, health and frailty at each follow up were the key features of the 4C study. As such, the 4C study was designed to study if and how patients' comorbidities and frailty are associated with the course of MCI and dementia measured with a comprehensive and multidimensional set of outcomes including cognition, daily functioning, quality of life, behavioral disturbances, caregiver burden, institutionalization and death and whether the effects of medical health and frailty differ between MCI and dementia stages of cognitive disorders. Conclusion: Sampled in a clinical setting, the 4C study complements population-based studies on neurodegenerative disorders in terms of the type of assessment (e.g. comorbidity, frailty, and functional status were repeatedly assessed). The 4C study complements available clinical cohorts of MCI and dementia patients, because the exclusion criteria were kept to a minimum, to obtain a sample that is representative for the average patient visiting a memory clinic. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
142. INTERDEM Academy: a training and career development initiative vital to capacity building of early stage psychosocial dementia researchers in Europe.
- Author
-
Klinkenberg, Inge P. M., de Oliveira, Déborah, Verhey, Frans R. J., Orrell, Martin, and de Vugt, Marjolein E.
- Subjects
DEMENTIA risk factors ,TREATMENT of dementia ,DEMENTIA ,HEALTH care teams ,INTERNATIONAL relations ,HEALTH policy ,NURSING education ,PERSONNEL management ,QUALITY of life ,SERIAL publications ,VOCATIONAL guidance ,SOCIAL support ,WELL-being ,PSYCHOLOGY of Research personnel - Abstract
The authors discuss several studies related to capacity building of early stage psychosocial dementia researchers in Europe. Topics covered include the needs and quality of life of people with dementia and their caregivers, the use and implementation of Dementia Care Mapping with the RE-AIM Framework to support care experts working in 12 group homes, and the effectiveness and acceptability of training interventions with a communication component aimed at target groups.
- Published
- 2019
- Full Text
- View/download PDF
143. The experiences and needs of children living with a parent with young onset dementia: results from the NeedYD study
- Author
-
Millenaar, Joany K., primary, van Vliet, Deliane, additional, Bakker, Christian, additional, Vernooij-Dassen, Myrra J. F. J., additional, Koopmans, Raymond T. C. M., additional, Verhey, Frans R. J., additional, and de Vugt, Marjolein E., additional
- Published
- 2013
- Full Text
- View/download PDF
144. Awareness and Its Association With Affective Symptoms in Young-onset and Late-onset Alzheimer Disease
- Author
-
van Vliet, Deliane, primary, de Vugt, Marjolein E., additional, Köhler, Sebastian, additional, Aalten, Pauline, additional, Bakker, Christian, additional, Pijnenburg, Yolande A.L., additional, Vernooij-Dassen, Myrra J. F. J., additional, Koopmans, Raymond T. C. M., additional, and Verhey, Frans R. J., additional
- Published
- 2013
- Full Text
- View/download PDF
145. Amyloid-β Interacts with Blood-Brain Barrier Function in Dementia: A Systematic Review
- Author
-
Burgmans, Saartje, primary, van de Haar, Harm J., additional, Verhey, Frans R. J., additional, and Backes, Walter H., additional
- Published
- 2013
- Full Text
- View/download PDF
146. Genetic Loci Associated with Alzheimer’s Disease and Cerebrospinal Fluid Biomarkers in a Finnish Case-Control Cohort
- Author
-
Elias-Sonnenschein, Lyzel S., primary, Helisalmi, Seppo, additional, Natunen, Teemu, additional, Hall, Anette, additional, Paajanen, Teemu, additional, Herukka, Sanna-Kaisa, additional, Laitinen, Marjo, additional, Remes, Anne M., additional, Koivisto, Anne M., additional, Mattila, Kari M., additional, Lehtimäki, Terho, additional, Verhey, Frans R. J., additional, Visser, Pieter Jelle, additional, Soininen, Hilkka, additional, and Hiltunen, Mikko, additional
- Published
- 2013
- Full Text
- View/download PDF
147. Depression and Risk of Mortality in People with Diabetes Mellitus: A Systematic Review and Meta-Analysis
- Author
-
van Dooren, Fleur E. P., primary, Nefs, Giesje, additional, Schram, Miranda T., additional, Verhey, Frans R. J., additional, Denollet, Johan, additional, and Pouwer, François, additional
- Published
- 2013
- Full Text
- View/download PDF
148. Determinants of Care Costs of Patients With Dementia or Cognitive Impairment
- Author
-
Handels, Ron L. H., primary, Wolfs, Claire A. G., additional, Aalten, Pauline, additional, Verhey, Frans R. J., additional, and Severens, Johan L., additional
- Published
- 2013
- Full Text
- View/download PDF
149. Added Prognostic Value of Cerebrospinal Fluid Biomarkers in Predicting Decline in Memory Clinic Patients in a Prospective Cohort.
- Author
-
Handels, Ron L. H., Joore, Manuela A., Vos, Stephanie J. B., Aalten, Pauline, Ramakers, Inez H. G. B., Rikkert, Marcel Olde, Scheltens, Philip, Jansen, Willemijn J., Visser, Pieter-Jelle, van Berckel, Bart M. N., van Domburg, Peter, Smid, Machiel, Hoff, Erik, Hoogmoed, Jan, Bouwman, Femke, Claassen, Jurgen, Leentjens, Albert F. G., Wolfs, Claire A. G., Severens, Johan L., and Verhey, Frans R. J.
- Subjects
ALZHEIMER'S disease research ,BRAIN disease research ,BIOMARKERS ,CEREBROSPINAL fluid ,LUMBAR puncture ,ALZHEIMER'S disease ,LONGITUDINAL method ,MEMORY disorders ,PROGNOSIS ,PSYCHOLOGICAL tests ,REFERENCE values ,DISEASE complications - Abstract
Background: Limited information is available on short-term prognosis of Alzheimer's disease (AD) biomarkers in cerebrospinal fluid (CSF) in addition to routine diagnostic workup.Objective: This study aims to investigate the added prognostic value of AD CSF biomarkers.Methods: In a prospective cohort study, clinical experts predicted cognitive and functional symptoms in 114 memory clinic patients by assessing comprehensive routine diagnostic test information (patient history, and physical, neurological, psychiatric, neuropsychological, and MRI examinations), without and with CSF biomarkers. The reference standard was the 'observed clinically relevant decline' using baseline and 1- and 2-year follow-up information.Results: Decline over a 2-year period was observed in 51% of all participants (3% in SMC, 48% in MCI, 90% in mild dementia). In the total sample, the accuracy of predicted decline did not differ significantly between routine assessment without (79% correctly predicted) and with (74% correctly predicted) CSF biomarkers. Subgroup analyses revealed 25 (83%) correct predictions in SMC, 30 (68%) in MCI, and 35 (88%) in dementia without the use of CSF; and 21 (70%), 27 (61%), and 36 (90%), respectively, with the use of CSF in addition to the routine assessment.Conclusion: AD CSF biomarkers did not increase accuracy of 2-year prognosis of cognitive and functional decline when added to routine diagnostic workup. This suggests that the standard diagnostic workup without CSF biomarkers allows fairly accurate predictions for the short-term course of symptoms. Routine AD biomarkers in CSF have limited prognostic value over 2 years in persons with a suspected cognitive disorder. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
150. The Impact of Young Onset Dementia on Informal Caregivers Compared with Late Onset Dementia: Results from the NeedYD Study.
- Author
-
Millenaar, Joany K., de Vugt, Marjolein E., Bakker, Christian, van Vliet, Deliane, Pijnenburg, Yolande A. L., Koopmans, Raymond T. C. M., and Verhey, Frans R. J.
- Abstract
Objectives: The impact of the dementia might be more severe for caregivers of people with young onset dementia (YOD) compared with those who care for someone with late onset dementia (LOD), as a young age among caregivers has been identified as a predictor of increased burden. The present study compares well-being between LOD and YOD caregivers longitudinally because this knowledge is essential in order to develop adequate support programs.Design, Setting, and Participants: 220 YOD and 108 LOD patient-caregiver dyads were included from two prospective cohorts with a 2-year follow up. To assess well-being we used the Short Sense of Competence Questionnaire, the RAND-36, the Symptom Checklist 90, and the Montgomery Asberg Depression Rating Scale. The severity and the course of the different measures used to describe caregiver burden were analyzed with linear mixed models.Results: Caregivers in both groups experienced high levels of physical and psychological complaints, mild depressive symptoms, lower health-related quality of life (HRQoL), and decreased feelings of competence. The severity and the course of most measures were similar in both groups, although HRQoL on both the physical and the mental domain was lower for the YOD caregivers.Conclusions: The number of actual psychological and physical complaints does not differ between YOD and LOD caregivers. YOD caregivers have greater perceived difficulties in daily life because of these complaints, however. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.